Peginterferon alfa-2a

Source: Wikipedia, the free encyclopedia.
(Redirected from
Interferon alfa 2a
)

Peginterferon alfa-2a
Clinical data
Trade namesPegasys, others
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa605029
License data
Pregnancy
category
  • AU: B3
Subcutaneous injection
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: WARNING[1]Rx-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC860H1353N227O255S9
Molar mass19241.16 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat

injection under the skin.[2]

Side effects are common.

pegylated to protect the molecule from breakdown.[5]

Pegylated interferon alfa-2a was approved for medical use in the United States in 2002.[2] It is on the World Health Organization's List of Essential Medicines.[6]

Medical uses

This drug is approved around the world for the treatment of chronic hepatitis C (including people with HIV co-infection, cirrhosis, 'normal' levels of ALT) and has recently been approved (in the EU, U.S., China and many other countries) for the treatment of chronic hepatitis B. It is also used in the treatment of certain T-cell lymphomas, particularly mycosis fungoides.[citation needed]

Peginterferon alfa-2a is a long acting interferon. Interferons are

viruses in the body, for regulating reproduction of cells, and for regulating the immune system.[7]

Host genetic factors

For genotype 1 hepatitis C treated with pegylated interferon alfa-2a or pegylated interferon alfa-2b combined with ribavirin, it has been shown that genetic polymorphisms near the human IL28B gene, encoding interferon lambda 3, are associated with significant differences in response to the treatment. This finding, originally reported in Nature,[8] showed genotype 1 hepatitis C patients carrying certain genetic variant alleles near the IL28B gene are more likely to achieve sustained virological response after the treatment than others. Another report in Nature demonstrated the same genetic variants are also associated with the natural clearance of the genotype 1 hepatitis C virus.[9]

Manufacturing

It is

pegylated with a branched 40 kg/mol PEG chain.[10]

Society and culture

Availability

Peginterferon alfa-2a is manufactured under the brand name Pegasys. In 2021,

Roche Pharmaceuticals sold the worldwide rights of Pegasys (excluding China and Japan) to zr pharma& GmbH (pharma&).[11][12][13][14][15] In May 2022, Roche Australia transferred the sales and marketing of Pegasys to Echo Therapeutics Pty Ltd.[16]

Research

A Cochrane Review sought to determine whether interferon alfa-2a could be used as a treatment for individuals with neovascular age-related macular degeneration. They found no evidence of improved visual acuity with potential harm.[17]

References

  1. FDA
    . Retrieved 22 October 2023.
  2. ^ a b c d e f g h "Peginterferon Alfa-2a (Professional Patient Advice) - Drugs.com". www.drugs.com. Archived from the original on 16 January 2017. Retrieved 12 January 2017.
  3. ^ "Pegasys 135 mcg and 180 mcg solution for injection in pre-filled pen - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. Archived from the original on 13 January 2017. Retrieved 12 January 2017.
  4. ISBN 9780857111562
    .
  5. ^ a b "Peginterferon alfa-2a (Pegasys) - Treatment - Hepatitis C Online". www.hepatitisc.uw.edu. Archived from the original on 23 December 2016. Retrieved 12 January 2017.
  6. hdl:10665/325771
    . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  7. ^ "Interferon alfa-2a Uses, Side Effects & Warnings". Drugs.com. Retrieved 10 January 2020.
  8. S2CID 1707096
    .
  9. PMID 19759533
    .
  10. PMID 12052715
    .
  11. ^ "Pegasys (peginterferon alfa-2a)". Genentech. Archived from the original on 8 January 2023. Retrieved 8 January 2023.
  12. ^ "Verzichtserklärung der Zulassung - Mittelfristig läuft Pegasys aus" (PDF). www.roche.de (German). Archived from the original (PDF) on 4 December 2021. Retrieved 4 December 2021.
  13. ^ "Pegasys (Peginterferon alfa-2a) langfristig weiterhin erhältlich" (PDF). Roche (in German). Archived from the original (PDF) on 4 December 2021. Retrieved 4 December 2021.
  14. ^ "pharma& portfolio". zr pharma& GmbH. Retrieved 4 December 2021.
  15. ^ "HALF-YEAR REPORT 2021, p.20" (PDF). Roche. Archived from the original (PDF) on 24 November 2021. Retrieved 4 December 2021.
  16. ^ "Pegasys". Roche Australia. Retrieved 8 January 2023.
  17. PMID 16437522
    .

External links

Wikimedia Commons has media related to Interferon-alpha 2a.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Peginterferon_alfa-2a&oldid=1214240864"